ABSTRACT
In 2014, the GlaxoSmithKline China Investment Co. (GSK) was found guilty of commercial bribery by the Chinese court. Apart from being punished with the largest corporate fine in China, senior executives of the company received prison sentences. This bribery case has received overwhelming attention both inside and outside of China. Some view it as the beginning of bolstering law enforcement in China against multinational companies (MNCs) which have long enjoyed privileges that Chinese domestic corporates lack, while others suspect that this demonstrates China’s increasingly frosty environment for foreign corporates.
